10,000 UK genomes project explores the contribution of rare variants to human disease and its risk factors

Landmark study confirms complexity and informs the next stages of research

10,000 UK genomes project explores the contribution of rare variants to human disease and its risk factors

uk10.jpg

The largest population genome sequencing effort to date is published today in Nature. A series of papers describing resources and application of the data is published at the same time in Nature, Nature Genetics, Bioinformatics and Nature Communications.

Rare genetic variants are changes in DNA that are carried only by relatively few people in a population. The UK10K study was designed to explore the contribution of these rare genetic variants to human disease and its risk factors.

"The project has made important new contributions towards describing the role of rare genetic variants in a broad range of disease scenarios and human traits. It has shown that the value of sequencing a few thousand individuals is high for highly penetrant, rare diseases, but that for complex traits and diseases much larger sample sizes will be required in future studies. The data and results produced by this project will be instrumental for these future efforts."

Dr Nicole Soranzo, corresponding author from the Wellcome Trust Sanger Institute

The project studied nearly 10,000 individuals, both healthy and affected by disease. The conditions included very rare disorders inherited in families, and more common diseases such as autism, schizophrenia and obesity. In healthy people, 64 different biomedical risk factors such as blood pressure or cholesterol levels were studied. By characterising the DNA sequence of these individuals, the project gained insight into the contribution of rare variants to a broad range of disease scenarios, and discovered new genetic variants and genes underpinning disease risk.

"The UK10K project has increased the resolution of genetic discoveries. It has enabled access to a much denser set of variants within the genome in the UK population, which can be used to refine our understanding of genetic effect on phenotypic traits. In earlier studies either very rare variants with big effects or common variants, which usually only have small effects, could be analysed. Now we have been able to explore an increased part of the spectrum of variation in between the very rare and the common ones."

Dr Richard Durbin, senior UK10K researcher at the Sanger Institute

A series of papers published today in Nature and Nature Genetics in collaboration with other investigators demonstrates the value of these data for genetic discoveries.

As efforts continue to characterise the genetic underpinnings of complex diseases, the data and results of this study are expected to enable the next wave of discoveries. The UK10K sequence reference panel, described in greater detail in a companion paper published in Nature Communications, has been shown to greatly increase the ability to characterise rare variants in large population samples available to the worldwide research community. This resource will enable researchers to 'fill in' missing data from lower resolution genotype studies, allowing them to explore full genotypes more quickly and cheaply.

In addition, the authors have developed a web-based browser of association based on the Dalliance platform, described in a companion paper in Bioinformatics. This genome browser allows the easy retrieval of association results for all disease risk traits analysed in the study. Scientists investigating these specific disease risk factors will be able to directly access the consequence of a person's DNA sequence to see how common any genetic variants they have are and what traits these variations are associated with.

"The UK10K project was an enormous undertaking and has laid the ground for future studies. For instance, the benefits of the new UK10K haplotype reference panel are already being realised in analyses of international consortia as well as the 0.5M people UK BioBank study."

Klaudia Walter, a leading author from the Sanger Institute

Notes to Editors
Publications
  • The UK10K project identifies rare variants in health and disease.

    UK10K Consortium, Walter K, Min JL, Huang J, Crooks L et al.

    Nature 2015;526;7571;82-90

  • Whole-genome sequencing identifies EN1 as a determinant of bone density and fracture.

    Zheng HF, Forgetta V, Hsu YH, Estrada K, Rosello-Diez A et al.

    Nature 2015;526;7571;112-7

  • Improved imputation of low-frequency and rare variants using the UK10K haplotype reference panel.

    Huang J, Howie B, McCarthy S, Memari Y, Walter K et al.

    Nature communications 2015;6;8111

  • An interactive genome browser of association results from the UK10K cohorts project.

    Geihs M, Yan Y, Walter K, Huang J, Memari Y et al.

    Bioinformatics (Oxford, England) 2015;31;24;4029-31

Also appearing in Nature Genetics:

Sidore C et al. Genome sequencing elucidates Sardinian genetic architecture and augments association analyses for lipid and blood inflammatory markers. Nature Genetics 2015. DOI: 10.1038/ng.3368

Danjou F et al. Genome-wide association analyses based on whole-genome sequencing in Sardinia provide insights into regulation of hemoglobin levels. Nature Genetics 2015. DOI: 10.1038/ng.3307

Zoledziewska M et al. Major height reducing variants and selection for short stature on the island of Sardinia. Nature Genetics 2015 DOI: 10.1038/ng.3403

Funding

The Wellcome Trust provided funding for UK10K (WT091310). Additional grant support and acknowledgements can be found in the paper.

Selected Websites
Contact the Press Office

Emily Mobley, Media Manager

Tel +44 (0)1223 496 851

Dr Samantha Wynne, Media Officer

Tel +44 (0)1223 492 368

Dr Matthew Midgley, Media Officer

Tel +44 (0)1223 494 856

Wellcome Sanger Institute,
Hinxton,
Cambridgeshire,
CB10 1SA,
UK

Mobile +44 (0) 7748 379849

Recent News

Appointments and changes to the Genome Research Limited Board
At the GRL Board meeting on 2 December 2019, David Willetts announced his intention to step down as Chair because of his extensive commitments across the academic and science sectors. Wellcome's Director, Jeremy Farrar, will take over the Chair of GRL Board from 1 January 2020.
Researchers identify new possibilities for the treatment of inflammatory bowel disease
Two molecular pathways found to be integral to maintaining balance in the digestive system
Root of childhood kidney cancer discovered
Pre-cancerous signatures found in healthy tissue point the way towards new treatment options